Switch theme
Sign up to access all valuation multiples
Founded in 2002 in South Korea, Celltrion is one of the largest biosimilar manufacturers around the world. Biosimilar drug sales accounted for 87% of its total revenue in 2024. Europe is the largest market for its biosimilar drug sales, contributing more than 47% of its total revenue, followed by 37% from the North America region and 16% from emerging markets. Besides biosimilar manufacturing, Celltrion entered the contract manufacturing business in 2024.
1991
n/a
LTM Revenue $2.9B
LTM EBITDA $906M
$30.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celltrion has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $906M.
In the most recent fiscal year, Celltrion achieved revenue of $2.6B and an EBITDA of $784M.
Celltrion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celltrion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | XXX | $2.6B | XXX | XXX | XXX |
| Gross Profit | $1.6B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $906M | XXX | $784M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| EBIT | $628M | XXX | $361M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $507M | XXX | $310M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $854M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Celltrion's stock price is KRW 180300 (or $132).
Celltrion has current market cap of KRW 40.82T (or $29.9B), and EV of KRW 42.07T (or $30.8B).
See Celltrion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.8B | $29.9B | XXX | XXX | XXX | XXX | $2.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Celltrion has market cap of $29.9B and EV of $30.8B.
Celltrion's trades at 11.8x EV/Revenue multiple, and 39.3x EV/EBITDA.
Equity research analysts estimate Celltrion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Celltrion has a P/E ratio of 59.0x.
See valuation multiples for Celltrion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $29.9B | XXX | $29.9B | XXX | XXX | XXX |
| EV (current) | $30.8B | XXX | $30.8B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 11.8x | XXX | XXX | XXX |
| EV/EBITDA | 34.0x | XXX | 39.3x | XXX | XXX | XXX |
| EV/EBIT | 49.1x | XXX | 85.5x | XXX | XXX | XXX |
| EV/Gross Profit | 19.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.0x | XXX | 96.6x | XXX | XXX | XXX |
| EV/FCF | 64.7x | XXX | 74.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCelltrion's last 12 month revenue growth is 20%
Celltrion's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Celltrion's rule of 40 is 63% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Celltrion's rule of X is 81% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Celltrion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 30% | XXX | XXX | XXX |
| EBITDA Growth | 43% | XXX | 27% | XXX | XXX | XXX |
| Rule of 40 | 63% | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 81% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celltrion acquired XXX companies to date.
Last acquisition by Celltrion was XXXXXXXX, XXXXX XXXXX XXXXXX . Celltrion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Celltrion founded? | Celltrion was founded in 1991. |
| Where is Celltrion headquartered? | Celltrion is headquartered in South Korea. |
| Who is the CEO of Celltrion? | Celltrion's CEO is Mr. Sung-Woo Ki. |
| Is Celltrion publicy listed? | Yes, Celltrion is a public company listed on KRX. |
| What is the stock symbol of Celltrion? | Celltrion trades under 068270 ticker. |
| When did Celltrion go public? | Celltrion went public in 2005. |
| Who are competitors of Celltrion? | Similar companies to Celltrion include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Celltrion? | Celltrion's current market cap is $29.9B |
| What is the current revenue of Celltrion? | Celltrion's last 12 months revenue is $2.9B. |
| What is the current revenue growth of Celltrion? | Celltrion revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Celltrion? | Current revenue multiple of Celltrion is 10.6x. |
| Is Celltrion profitable? | Yes, Celltrion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Celltrion? | Celltrion's last 12 months EBITDA is $906M. |
| What is Celltrion's EBITDA margin? | Celltrion's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Celltrion? | Current EBITDA multiple of Celltrion is 34.0x. |
| What is the current FCF of Celltrion? | Celltrion's last 12 months FCF is $477M. |
| What is Celltrion's FCF margin? | Celltrion's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Celltrion? | Current FCF multiple of Celltrion is 64.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
